Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prulifloxacin · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Tablet |
| 2 | PLACEBO_COMPARATOR | Tablet |
| Name | Type | Description |
|---|---|---|
| prulifloxacin | DRUG | Tablet |
| Placebo | DRUG | Tablet |
Inclusion Criteria: * Diagnosis of acute bacterial gastroenteritis * Traveler from an industrialized country * Capable of giving Informed Consent Exclusion Criteria: * Fever (\>100.3 degrees) * Pregnant or Breast Feeding or Not using adequate birth control * Known or Suspected (co-)Infection with...
Prulifloxacin is an investigational small molecule being studied for the treatment of acute gastroenteritis in adult travelers and acute bacterial gastroenteritis. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 3 clinical development.
Prulifloxacin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication. This action leads to the death of susceptible bacteria, making it effective against gastrointestinal pathogens causing acute gastroenteritis.
Prulifloxacin is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 3 clinical trials for acute gastroenteritis in adult travelers.
Prulifloxacin is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed to evaluate its safety and efficacy in treating acute gastroenteritis in adult travelers.
Prulifloxacin has been studied in two completed Phase 3 clinical trials. NCT00392574 enrolled 282 participants in the United States, and NCT00448422 enrolled 268 participants in India. Both trials were randomized, double-blind, placebo-controlled studies evaluating the drug for acute gastroenteritis in adult travelers.
Prulifloxacin is a fluoroquinolone antibiotic, a class that includes drugs like ciprofloxacin and levofloxacin. However, Prulifloxacin is a distinct compound with its own chemical structure and is being developed specifically for acute gastroenteritis in adult travelers.